Mandate

Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.

Related

Vinge advises Consolid Equity in connection with the establishment of Petra Group

Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026